Nemaura Medical (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today reported data from an interim analysis of the first of a number of planned studies in support of a submission to the U.S Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product.

Why It Matters: SugarBEAT® is expected to launch in the UK in the coming months, and is expected to be marketed to all categories of diabetics, including Type 1, Type 2 and pre-diabetics. Continuous Glucose Monitoring (CGM) is estimated to have a global total addressable market worth $82 billion. The U.S. has the largest number of CGM users, where 2018 usage numbers are estimated at 630,000 insulin users, representing 2.6% of 24.6 million people who have been diagnosed with diabetes.

What's Next: Completion of U.S. study and FDA submission is anticipated in Q1 2019, alongside poster presentation at the Advanced Technologies & Treatment for Diabetes (ATTD) conference in Berlin in February 2019 for the full in-clinic portion, which is designed to record approximately 16,000 matched data points.

Disclosure

Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. Nemaura Medical pays RedChip a monthly cash fee for investor awareness services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics.

Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, is pleased to announce a new development from the United States Patent Office in its continued prosecution of critical patents for the law enforcement community.

The Patent Office has granted Digital Ally two new patents: U.S. Patent Nos. 10,074,394 (“the ’394 Patent”) and 10,075,681 (“the ’681 Patent”). These patents will be critical for assisting Law Enforcement Officers capture and collect evidence.

Key Quote: “We are excited that the Patent Office continues to recognize the pioneering work of our engineering team at Digital. We have always prided ourselves on our ability to out-innovate even our largest competitors.” Digital Ally’s CEO, Stanton E. Ross

The Backstory: Digital Ally develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial applications. The Company's primary focus is digital video imaging and storage. The Company is headquartered in Lenexa, Kansas, and its shares are traded on The Nasdaq Capital Market under the symbol DGLY.

Disclosure

Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.

In August we covered the Alternative Harvest ETF, one of the largest cannabis related ETFs currently traded. Since then the price has soared from just over $25 to more than $37 per share.

Growing interest from beverage companies and other more traditional businesses has sent a buying frenzy into the space over the past several weeks. While much of the interest has remained north of the border due to the Canadian government’s vote to end prohibition, we believe it’s a great sign longer-term for all cannabis related companies, and it’s likely only a matter of time before US-based players catch up.